Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Int. braz. j. urol ; 41(5): 849-858, Sept.-Oct. 2015. tab, graf
Article Dans Anglais | LILACS | ID: lil-767051

Résumé

ABSTRACT Introduction and Objectives: Reactive Stroma (RStr) is observed in many human cancers and is related to carcinogenesis. The objectives of the present study were to stablish a relationship of the RStr microenvironment with prostate cancer (Pca) through a morphological and molecular characterization, and to identify a possible relationship between RStr with worse prognosis factors and occurrence of malignant prostatic stem cells. Materials and Methods: Forty prostatic samples were selected from men with Pca diagnosis submitted to radical prostatectomy; they were divided in two groups: Group-1 (n=20): samples without reactive stroma; Group-2 (n=20): samples of PCa with intense stroma reaction. Prostatic samples were evaluated for RStr intensity by Masson Trichromic stain and posteriorly submitted to histopathological and immunohistochemistry analysis for antigens: α-actin, vimentin, IGF-1, MMP-2, FGF-2, C-Myc, PSCA, AR, Erα and ERβ. Results: Reactive stroma with intense desmoplastic reactivity was significantly more frequent in intermediate (Gleason 7, 3+4) and high grade tumors (Gleason 7, 4+3). The group with intense stromal reactivity showed significant higher levels of Vimentin, IGF-1, MMP-2, FGF-2, C-Myc, PSCA and ERα. Conclusions: It can be concluded that RStr may be a predictive marker of Pca progression, since it was associated with increase of growth factors, imbalance of androgen and estrogen receptors and presence of malign prostatic stem cells.


Sujets)
Sujet âgé , Sujet âgé de 80 ans ou plus , Humains , Mâle , Adulte d'âge moyen , Adénocarcinome/anatomopathologie , Cellules épithéliales/anatomopathologie , Cellules souches tumorales/anatomopathologie , Tumeurs de la prostate/anatomopathologie , Cellules stromales/anatomopathologie , Actines/analyse , Adénocarcinome/composition chimique , Antigènes néoplasiques/analyse , Marqueurs biologiques tumoraux/analyse , Évolution de la maladie , Protéines de liaison à l'ADN/analyse , Cellules épithéliales/composition chimique , Récepteur alpha des oestrogènes/analyse , /analyse , Protéines liées au GPI/analyse , Immunohistochimie , Facteur de croissance IGF-I/analyse , /analyse , Grading des tumeurs , Protéines tumorales/analyse , Cellules souches tumorales/composition chimique , Tumeurs de la prostate/composition chimique , Cellules stromales/composition chimique , Microenvironnement tumoral , Facteurs de transcription/analyse , Vimentine/analyse
2.
Braz. j. med. biol. res ; 48(6): 557-567, 06/2015. tab, graf
Article Dans Anglais | LILACS | ID: lil-748226

Résumé

Hyaluronan (HA) shows promise for detecting cancerous change in pleural effusion and urine. However, there is uncertainty about the localization of HA in tumor tissue and its relationship with different histological types and other components of the extracellular matrix, such as angiogenesis. We evaluated the association between HA and degree of malignancy through expression in lung tumor tissue and sputum. Tumoral tissue had significantly increased HA compared to normal tissue. Strong HA staining intensity associated with cancer cells was significant in squamous cell carcinoma compared to adenocarcinoma and large cell carcinoma. A significant direct association was found between tumors with a high percentage of HA and MVD (microvessel density) in tumoral stroma. Similarly significant was the direct association between N1 tumors and high levels of HA in cancer cells. Cox multivariate analysis showed significant association between better survival and low HA. HA increased in sputum from lung cancer patients compared to cancer-free and healthy volunteers and a significant correlation was found between HA in sputum and HA in cancer tissue. Localization of HA in tumor tissue was related to malignancy and reflected in sputum, making this an emerging factor for an important diagnostic procedure in patients suspected to have lung cancer. Further study in additional patients in a randomized prospective trial is required to finalize these results and to validate our quantitative assessment of HA, as well as to couple it to gold standard sputum cytology.


Sujets)
Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Carcinomes/composition chimique , Acide hyaluronique/analyse , Tumeurs du poumon/composition chimique , Expectoration/composition chimique , Biopsie , Marqueurs biologiques tumoraux/analyse , Études cas-témoins , Carcinomes/anatomopathologie , Test ELISA , Immunohistochimie , Tumeurs du poumon/anatomopathologie , Poumon/composition chimique , Poumon/anatomopathologie , Stadification tumorale , Reproductibilité des résultats , Facteurs de risque , Sensibilité et spécificité , Statistique non paramétrique , Fumer/effets indésirables , Cellules stromales/composition chimique , Cellules stromales/anatomopathologie
SÉLECTION CITATIONS
Détails de la recherche